FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130651303> ?p ?o ?g. }

• W2130651303 endingPage "4244" @default.
• W2130651303 startingPage "4238" @default.
• W2130651303 abstract "The management of early-stage Hodgkin's disease in the United States is controversial. To evaluate whether staging laparotomy could be safely avoided in early-stage Hodgkin's disease and whether chemotherapy should be a part of the treatment of nonlaparotomy staged patients, a phase III intergroup trial was performed.Three hundred forty-eight patients with clinical stage IA to IIA supradiaphragmatic Hodgkin's disease were randomized without staging laparotomy to treatment with either subtotal lymphoid irradiation (STLI) or combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by STLI.The study was closed at the second, planned, interim analysis because of a markedly superior failure-free survival (FFS) rate for patients on the CMT arm (94%) compared with the STLI arm (81%). With a median follow-up of 3.3 years, 10 patients have experienced relapse or died on the chemoradiotherapy arm, compared with 34 on the radiotherapy arm (P <.001). Few deaths have occurred on either arm (three deaths on CMT and seven deaths on STLI). Treatment was well tolerated, with only one death on each arm attributed to treatment.These results demonstrate that it is possible to obtain a high FFS rate in a large group of stage IA to IIA patients without performing staging laparotomy and that three cycles of chemotherapy plus STLI provide a superior FFS compared with STLI alone. Extended follow-up is necessary to assess freedom from second relapse, overall survival, late toxicities, patterns of treatment failure, and quality of life." @default.
• W2130651303 created "2016-06-24" @default.
• W2130651303 creator A5009574158 @default.
• W2130651303 creator A5009883349 @default.
• W2130651303 creator A5034493174 @default.
• W2130651303 creator A5041539801 @default.
• W2130651303 creator A5049875077 @default.
• W2130651303 creator A5070128429 @default.
• W2130651303 creator A5071127912 @default.
• W2130651303 creator A5074206651 @default.
• W2130651303 creator A5078791373 @default.
• W2130651303 creator A5091192260 @default.
• W2130651303 date "2001-11-15" @default.
• W2130651303 modified "2023-10-03" @default.
• W2130651303 title "Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease" @default.
• W2130651303 cites W1536128075 @default.
• W2130651303 cites W1829707378 @default.
• W2130651303 cites W1883598689 @default.
• W2130651303 cites W1894084104 @default.
• W2130651303 cites W1912609891 @default.
• W2130651303 cites W1917085797 @default.
• W2130651303 cites W1936844651 @default.
• W2130651303 cites W1971696227 @default.
• W2130651303 cites W1973037952 @default.
• W2130651303 cites W2006194674 @default.
• W2130651303 cites W2010230072 @default.
• W2130651303 cites W2016346747 @default.
• W2130651303 cites W2016639669 @default.
• W2130651303 cites W2021699851 @default.
• W2130651303 cites W2024291302 @default.
• W2130651303 cites W2041355841 @default.
• W2130651303 cites W2051536310 @default.
• W2130651303 cites W2073286025 @default.
• W2130651303 cites W2115117264 @default.
• W2130651303 cites W2115919161 @default.
• W2130651303 cites W2119809479 @default.
• W2130651303 cites W2131969355 @default.
• W2130651303 cites W2132976876 @default.
• W2130651303 cites W2136776601 @default.
• W2130651303 cites W2164271313 @default.
• W2130651303 cites W2165308914 @default.
• W2130651303 cites W2177081274 @default.
• W2130651303 cites W2248977291 @default.
• W2130651303 cites W2257114268 @default.
• W2130651303 cites W2274334418 @default.
• W2130651303 cites W2409218061 @default.
• W2130651303 cites W3147894994 @default.
• W2130651303 cites W4211250890 @default.
• W2130651303 doi "https://doi.org/10.1200/jco.2001.19.22.4238" @default.
• W2130651303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11709567" @default.
• W2130651303 hasPublicationYear "2001" @default.
• W2130651303 type Work @default.
• W2130651303 sameAs 2130651303 @default.
• W2130651303 citedByCount "142" @default.
• W2130651303 countsByYear W21306513032012 @default.
• W2130651303 countsByYear W21306513032013 @default.
• W2130651303 countsByYear W21306513032014 @default.
• W2130651303 countsByYear W21306513032015 @default.
• W2130651303 countsByYear W21306513032016 @default.
• W2130651303 countsByYear W21306513032017 @default.
• W2130651303 countsByYear W21306513032018 @default.
• W2130651303 countsByYear W21306513032019 @default.
• W2130651303 countsByYear W21306513032020 @default.
• W2130651303 countsByYear W21306513032021 @default.
• W2130651303 crossrefType "journal-article" @default.
• W2130651303 hasAuthorship W2130651303A5009574158 @default.
• W2130651303 hasAuthorship W2130651303A5009883349 @default.
• W2130651303 hasAuthorship W2130651303A5034493174 @default.
• W2130651303 hasAuthorship W2130651303A5041539801 @default.
• W2130651303 hasAuthorship W2130651303A5049875077 @default.
• W2130651303 hasAuthorship W2130651303A5070128429 @default.
• W2130651303 hasAuthorship W2130651303A5071127912 @default.
• W2130651303 hasAuthorship W2130651303A5074206651 @default.
• W2130651303 hasAuthorship W2130651303A5078791373 @default.
• W2130651303 hasAuthorship W2130651303A5091192260 @default.
• W2130651303 hasConcept C126322002 @default.
• W2130651303 hasConcept C141071460 @default.
• W2130651303 hasConcept C146357865 @default.
• W2130651303 hasConcept C151730666 @default.
• W2130651303 hasConcept C2776694085 @default.
• W2130651303 hasConcept C2777132456 @default.
• W2130651303 hasConcept C2778476748 @default.
• W2130651303 hasConcept C2780039790 @default.
• W2130651303 hasConcept C2780778865 @default.
• W2130651303 hasConcept C509974204 @default.
• W2130651303 hasConcept C71924100 @default.
• W2130651303 hasConcept C86803240 @default.
• W2130651303 hasConceptScore W2130651303C126322002 @default.
• W2130651303 hasConceptScore W2130651303C141071460 @default.
• W2130651303 hasConceptScore W2130651303C146357865 @default.
• W2130651303 hasConceptScore W2130651303C151730666 @default.
• W2130651303 hasConceptScore W2130651303C2776694085 @default.
• W2130651303 hasConceptScore W2130651303C2777132456 @default.
• W2130651303 hasConceptScore W2130651303C2778476748 @default.
• W2130651303 hasConceptScore W2130651303C2780039790 @default.
• W2130651303 hasConceptScore W2130651303C2780778865 @default.
• W2130651303 hasConceptScore W2130651303C509974204 @default.
• W2130651303 hasConceptScore W2130651303C71924100 @default.

• next